Interchangeability of two versions of the Montreal Cognitive Assessment for the longitudinal evaluation of patients with breast cancer.


Journal

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957

Informations de publication

Date de publication:
Mar 2022
Historique:
received: 08 04 2021
accepted: 15 11 2021
pubmed: 25 11 2021
medline: 1 2 2022
entrez: 24 11 2021
Statut: ppublish

Résumé

The cognitive performance of patients with breast cancer (BCa) may be affected by cancer and its treatments. The Montreal Cognitive Assessment (MoCA) is a widely used cognitive impairment screening tool, but practice effects must be considered for longitudinal assessments. Since learning effects could be overcome through the alternate use of two versions of the MoCA, we aimed to explore their interchangeability by comparing their overall, and domain- and task-specific, scores among patients with BCa. BCa patients from the NEON-BC cohort were evaluated with the MoCA, version 7.1, after diagnosis and after 1 year. At the 3-year follow-up (n = 422), the 7.1 and 7.3 versions were applied at the beginning and at the end (approximately 1 h later) of this evaluation, respectively. Agreements between versions, regarding total, sub-domain, and task scores, were assessed using Bland-Altman plots and intraclass correlation coefficients (ICC). The mean total scores were not statistically different between versions and the ICC was 0.890. The Bland-Altman limits of agreement were - 3.70 to 3.88. For women with midrange scores, total scores were significantly higher in version 7.1. There were significant differences in the percentage of correct answers in 7 out of 12 tasks, being the highest for the copy of a geometric figure (more than twofold higher with version 7.3). In version 7.1, the language and memory domains presented higher scores and lower visuospatial ability. Despite similar overall scores being obtained with the two versions of the MoCA, there were item-specific differences that may compromise their interchangeable use.

Identifiants

pubmed: 34817694
doi: 10.1007/s00520-021-06702-y
pii: 10.1007/s00520-021-06702-y
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2639-2647

Subventions

Organisme : European Regional Development Fund
ID : POCI-01-0145-FEDER-016867
Organisme : European Regional Development Fund
ID : POCI-01-0145-FEDER-032358
Organisme : Fundação para a Ciência e a Tecnologia
ID : PTDC/DTP-EPI/7183/2014
Organisme : Fundação para a Ciência e a Tecnologia
ID : SFRH/BD/119390/2016
Organisme : Fundação para a Ciência e a Tecnologia
ID : SFRH/BD/92630/2013
Organisme : Fundação para a Ciência e a Tecnologia
ID : PTDC/SAU-EPI/32358/2017
Organisme : Fundação para a Ciência e a Tecnologia
ID : UIDB/04750/2020

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Ahles TA (2012) Brain vulnerability to chemotherapy toxicities Psycho-Oncology 21:1141–1148
pubmed: 23023994
Joly F, Giffard B, Rigal O, De Ruiter MB, Small BJ, Dubois M, LeFel J, Schagen SB, Ahles TA, Wefel JS, Vardy JL, Pancré V, Lange M (2012) Castel H (2015) Impact of cancer and its treatments on cognitive function: advances in research From the Paris International Cognition and Cancer Task Force Symposium and Update Since. J Pain Symptom Manage 50:830–841
doi: 10.1016/j.jpainsymman.2015.06.019
Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53:695–699
doi: 10.1111/j.1532-5415.2005.53221.x
Isenberg-Grzeda E, Huband H, Lam H (2017) A review of cognitive screening tools in cancer. Current Opinion in Supportive and Palliative Care 11:24–31
doi: 10.1097/SPC.0000000000000257
Araújo N, Severo M, Lopes-Conceição L, Fontes F, Dias T, Branco M, Morais S, Cruz VT, Ruano L, Pereira S (2021) Trajectories of cognitive performance over five years in a prospective cohort of patients with breast cancer (NEON-BC). Breast 58:130–137
doi: 10.1016/j.breast.2021.05.006
Cooley SA, Heaps JM, Bolzenius JD, Salminen LE, Baker LM, Scott SE, Paul RH (2015) Longitudinal change in performance on the Montreal Cognitive Assessment in older adults. The Clinical neuropsychologist 29:824–835
doi: 10.1080/13854046.2015.1087596
Nasreddine Z, Phillips N, Chertkow H (2011) MoCA Version 2. In: Editor (ed)^(eds) Book MoCA Version 2, City
Nasreddine Z, Phillips N, Chertkow H (2011) MoCA Version 3. In: Editor (ed)^(eds) Book MoCA Version 3, City
Bruijnen CJ, Dijkstra BA, Walvoort SJ, Budy MJ, Beurmanjer H, De Jong CA, Kessels RP (2020) Psychometric properties of the Montreal Cognitive Assessment (MoCA) in healthy participants aged 18–70. Int J Psychiatry Clin Pract 24(3):293–300
doi: 10.1080/13651501.2020.1746348
Costa AS, Fimm B, Friesen P, Soundjock H, Rottschy C, Gross T, Eitner F, Reich A, Schulz JB, Nasreddine ZS (2012) Alternate-form reliability of the Montreal cognitive assessment screening test in a clinical setting. Dement Geriatr Cogn Disord 33:379–384
doi: 10.1159/000340006
Siciliano M, Chiorri C, Passaniti C, Sant’Elia V, Trojano L, Santangelo G (2019) Comparison of alternate and original forms of the Montreal Cognitive Assessment (MoCA): an Italian normative study. Neurological Sciences 40:691–702
doi: 10.1007/s10072-019-3700-7
Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society 53:695–699
doi: 10.1111/j.1532-5415.2005.53221.x
Freitas S, Simões M, Santana I, Martins C, Nasreddine Z (2013) Montreal Cognitive Assessment (MoCA): Versão 1. Laboratório de Avaliação Psicológica, Faculdade de Psicologia e de Ciências da Educação da Universidade de Coimbra, Coimbra
Freitas S, Simões M, Santana I, Martins C, Nasreddine Z (2013) Montreal Cognitive Assessment (MoCA): Versão 3. Laboratório de Avaliação Psicológica, Faculdade de Psicologia e de Ciências da Educação da Universidade de Coimbra, Coimbra
Freitas S, Simoes MR, Alves L, Santana I (2011) Montreal Cognitive Assessment (MoCA): normative study for the Portuguese population. Journal of clinical and experimental neuropsychology 33:989–996
doi: 10.1080/13803395.2011.589374
Pereira S, Fontes F, Sonin T, Dias T, Fragoso M, Castro-Lopes J, Lunet N (2014) Neurological complications of breast cancer: study protocol of a prospective cohort study. BMJ open 4:e006301
doi: 10.1136/bmjopen-2014-006301
McNemar Q (1947) Note on the sampling error of the difference between correlated proportions or percentages. Psychometrika 12:153–157
doi: 10.1007/BF02295996
Bland JM, Altman D (1986) Statistical methods for assessing agreement between two methods of clinical measurement. The lancet 327:307–310
doi: 10.1016/S0140-6736(86)90837-8
Koo TK, Li MY (2016) A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med 15:155–163
doi: 10.1016/j.jcm.2016.02.012
Looney MA (2000) When is the intraclass correlation coefficient misleading? Meas Phys Educ Exerc Sci 4:73–78
doi: 10.1207/S15327841Mpee0402_3
Krishnan K, Rossetti H, Hynan LS, Carter K, Falkowski J, Lacritz L, Cullum CM, Weiner M (2017) Changes in Montreal Cognitive Assessment scores over time. Assessment 24:772–777
doi: 10.1177/1073191116654217
Popović IM, Šerić V, Demarin V (2007) Mild cognitive impairment in symptomatic and asymptomatic cerebrovascular disease. J Neurol Sci 257:185–193
doi: 10.1016/j.jns.2007.01.029
Lebedeva E, Huang M, Koski L (2016) Comparison of alternate and original items on the Montreal Cognitive Assessment. Canadian Geriatrics Journal 19:15
doi: 10.5770/cgj.19.216
Heun R, Kockler M (2002) Gender differences in the cognitive impairment in Alzheimer’s disease Archives of Women’s Mental. Health 4:129–137

Auteurs

Natália Araújo (N)

EPIUnit - Instituto de Saúde Pública da Universidade do Porto, Porto, Portugal.
Laboratório para a Investigação Integrativa e Translacional em Saúde Populacional (ITR), Porto, Portugal.

Luisa Lopes-Conceição (L)

EPIUnit - Instituto de Saúde Pública da Universidade do Porto, Porto, Portugal.

Samantha Morais (S)

EPIUnit - Instituto de Saúde Pública da Universidade do Porto, Porto, Portugal.
Laboratório para a Investigação Integrativa e Translacional em Saúde Populacional (ITR), Porto, Portugal.
Departamento de Ciências da Saúde Pública e Forenses e Educação Médica, Faculdade de Medicina da Universidade do Porto, Porto, Portugal.

Filipa Fontes (F)

EPIUnit - Instituto de Saúde Pública da Universidade do Porto, Porto, Portugal.
Laboratório para a Investigação Integrativa e Translacional em Saúde Populacional (ITR), Porto, Portugal.
Instituto Português de Oncologia do Porto, Porto, Portugal.

Teresa Dias (T)

Instituto Português de Oncologia do Porto, Porto, Portugal.

Vítor Tedim Cruz (VT)

EPIUnit - Instituto de Saúde Pública da Universidade do Porto, Porto, Portugal.
Laboratório para a Investigação Integrativa e Translacional em Saúde Populacional (ITR), Porto, Portugal.
Hospital Pedro Hispano, Unidade Local de Saúde de Matosinhos, Senhora da Hora, Portugal.

Luís Ruano (L)

EPIUnit - Instituto de Saúde Pública da Universidade do Porto, Porto, Portugal.
Laboratório para a Investigação Integrativa e Translacional em Saúde Populacional (ITR), Porto, Portugal.
Centro Hospitalar Entre Douro e Vouga, Santa Maria da Feira, Portugal.

Susana Pereira (S)

EPIUnit - Instituto de Saúde Pública da Universidade do Porto, Porto, Portugal.
Laboratório para a Investigação Integrativa e Translacional em Saúde Populacional (ITR), Porto, Portugal.
Instituto Português de Oncologia do Porto, Porto, Portugal.

Nuno Lunet (N)

EPIUnit - Instituto de Saúde Pública da Universidade do Porto, Porto, Portugal. nlunet@med.up.pt.
Laboratório para a Investigação Integrativa e Translacional em Saúde Populacional (ITR), Porto, Portugal. nlunet@med.up.pt.
Departamento de Ciências da Saúde Pública e Forenses e Educação Médica, Faculdade de Medicina da Universidade do Porto, Porto, Portugal. nlunet@med.up.pt.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH